The multiplication of genes located in extrachromosomal DNA that have the potential to cause cancer drives poor patient outcomes across many cancer types, according to a Nature Genetics study ...

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, ...

A team of pediatric oncologists led by PD Dr. Anton G. Henssen has set out to further improve our understanding of the mechanisms involved in cancer development and disease progression. PD Dr. Henssen ...

POTENTIATE (Precision Oncology Trial Evaluating Novel Therapeutic Interrupting Amplifications Tied to ecDNA) is a first-in-human, 3-part, Phase 1/2 study of BBI-355 as a single agent and in ...

The multiplication of genes located in extrachromosomal DNA that have the potential to cause cancer drives poor patient outcomes across many cancer types, according to a Nature Genetics study ...

To the untrained eye, the tiny spots in the tumor cell wouldn’t look like much. In fact, other scientists had noticed them in cancer before but had generally dismissed them as a mere curiosity. But to ...

Something to look forward to: A multi-disciplinary team of researchers has pinpointed the major role played by extrachromosomal DNA in the evolution of carcinogenic diseases. This kind of "external" ...

Researchers led by Ludwig San Diego Member Don Cleveland and Peter Campbell of the Sanger Center have solved the mystery of how free-floating circular DNA fragments, which are almost exclusively found ...

Floating inside some cancer cells are bits of circle-shaped genetic material that are separate from chromosomes. Scientists observed them for decades, thinking they were just cellular debris without ...

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene ...

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to ...